Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells ; volume:41 ; number:1 ; day:5 ; month:12 ; year:2023 ; pages:1-12 ; date:1.2024
Medical oncology ; 41, Heft 1 (5.12.2023), 1-12, 1.2024
- Creator
-
Dewidar, Samar A.
Hamdy, Omar
Soliman, Moetaza M.
El Gayar, Amal M.
El-Mesery, Mohamed
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12032-023-02248-7
- URN
-
urn:nbn:de:101:1-2024032210084145495989
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dewidar, Samar A.
- Hamdy, Omar
- Soliman, Moetaza M.
- El Gayar, Amal M.
- El-Mesery, Mohamed
- SpringerLink (Online service)
Other Objects (12)
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation
A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells
Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer
Cyclophosphamide in combination with tumor lysate and TLR9 ligand regresses murine neuroblastoma
Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts
Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation
A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells
Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer
Cyclophosphamide in combination with tumor lysate and TLR9 ligand regresses murine neuroblastoma
Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts
Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation
A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation
A case of doxorubicin and cyclophosphamide therapy-induced type 1 diabetes: a case report
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells
Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer
Cyclophosphamide in combination with tumor lysate and TLR9 ligand regresses murine neuroblastoma
Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts